Summit Global Investments’s Collegium Pharmaceutical COLL Stock Holding History

Summit Global Investments’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,955	Closed	-$237K	–	477
2025 Q1	$237K	Sell	7,955 -153	-2%	-$4.68K	0.02%	392
2024 Q4	$232K	Buy	+8,108	New	+$268K	0.01%	487
2023 Q2	–	Sell	-96,485	Closed	-$2.31M	–	552
2023 Q1	$2.31M	Sell	96,485 -1,816	-2%	-$48.2K	0.18%	120
2022 Q4	$2.28M	Buy	98,301 +367	+0.4%	+$7.4K	0.19%	124
2022 Q3	$1.57M	Sell	97,934 -12,672	-11%	-$223K	0.15%	153
2022 Q2	$1.96M	Buy	110,606 +56,306	+104%	+$947K	0.17%	136
2022 Q1	$1.11M	Sell	54,300 -25,800	-32%	-$487K	0.08%	222
2021 Q4	$1.5M	Buy	80,100 +11,100	+16%	+$216K	0.1%	182
2021 Q3	$1.36M	Buy	69,000 +40,300	+140%	+$871K	0.1%	167
2021 Q2	$678K	Buy	+28,700	New	+$663K	0.04%	289

Other funds holding COLL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Summit Global Investments's COLL Position: Q2 2025 in Review

Summit Global Investments sold out of Collegium Pharmaceutical (COLL) in Q2 2025, closing a stake of 7,955 shares — an estimated $237K sold.

Summit Global Investments first reported a position in COLL in Q2 2021 and held it in 10 quarters. The position peaked at $2.31M in Q1 2023. 223 funds tracked by Wall St. Rank hold COLL as of Q2 2025.

Summit Global Investments reported no remaining Collegium Pharmaceutical position as of Q2 2025 after selling out during the quarter.
Summit Global Investments sold 7,955 Collegium Pharmaceutical shares in Q2 2025, an estimated $237K.
Summit Global Investments first reported a position in Collegium Pharmaceutical in Q2 2021 and held it in 10 quarters.
Summit Global Investments's Collegium Pharmaceutical position peaked at $2.31M in Q1 2023.
223 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2025.

Based on Summit Global Investments's 13F filing for Q2 2025, filed 12 Aug 2025.